|Chemical and physical data|
|Molar mass||505.65 g/mol|
|3D model (Jmol)||Interactive image|
Telapristone (INN), as telapristone acetate (proposed trade names Proellex, Progenta; former code name CDB-4124), is an investigational selective progesterone receptor modulator (SPRM) being studied for the treatment of certain progesterone-sensitive conditions. It was originally developed by the National Institutes of Health (NIH), and as of 2012, is in phase II clinical trials for the treatment of uterine fibroids and endometriosis. In addition to its actions as an SPRM, telapristone also has some antiglucocorticoid activity.
- Attardi BJ, Burgenson J, Hild SA, Reel JR (2004). "In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone". J Steroid Biochem Mol Biol. 88 (3): 277–88. doi:10.1016/j.jsbmb.2003.12.004. PMID 15120421.